Richard Lehman’s journal review—27 March 2017
Richard Lehman reviews the latest research in the leading medical journals […]
Richard Lehman reviews the latest research in the leading medical journals […]
NEJM 16 Mar 2017 Vol 376 Stem cells for AMD For sufferers of age-related macular degeneration who were hoping for a stem cell cure, this week’s New England Journal brings […]
NEJM 9 Mar 2017 Vol 376 Impressive imatinib In my childhood, somebody behaving self-importantly was referred to as “his nibs.” Today, the nibs of medicine are very proud of themselves. […]
Richard Lehman reviews the latest research in the leading medical journals. […]
NEJM 23 Feb 2017 Vol 376 Kallikrein rises from the footnotes The curious word “kallikrein” first appeared in 1934, when Eugen Werle discovered an inflammatory chemical in plasma which he […]
Doctors see people die, often in circumstances that they would wish to avoid for themselves. Dying is a part of daily life on stroke wards, major trauma units, elderly care […]
NEJM 16 Feb 2017 Vol 376 Periviable infant outcomes “Periviable” is a new word to me. I think I shall start using it for pieces of cheese that have been […]
NEJM 9 Feb 2017 Vol 376 Middle East Respiratory Syndrome Remember MERS? It was the talk of the town five years ago when it was first identified in Saudi Arabia. […]
NEJM 2 Feb 2017 Vol 376 Adding bicalutamide to RT for recurrent prostate cancer So far, this year is proving a good one for urology studies. Here are the follow-up […]
NEJM 26 Jan 2017 Vol 376 Bezlotoxumab Bezlotoxumab is an antibody that offers passive protection against Clostridium difficile toxin. This trial shows that if you give it with anti-clostridial antibiotics, […]